Jacob Laubach, Md

This study tests whether adding the investigational drug isatuximab to a standard three-drug regimen can improve outcomes for people newly diagnosed with multiple myeloma, a blood cancer. About 52 adults aged up to 75 will receive the combination. The main goal is to see how many…